1-3 of 3
Rodger Tiedemann, MD PhD
Close
Sort by
Journal Articles

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Abi Vijenthira, MD, Manjula Mangati, Michael Crump, MD, Vishal Kukreti, MD, John Kuruvilla, MD, Rodger Tiedemann, MD PhD, Christine Chen, MD, Anca Prica, MD
Journal: Blood
Blood (2016) 128 (22): 1795.
https://doi.org/10.1182/blood.V128.22.1795.1795
Published: 2016
Journal Articles

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Julie Cote, MD, Madeline Phillips, Eshetu G Atenafu, MSc, PStat, Esther Masih-Khan, PhD, Donna Reece, MD, Christine Chen, MD, Anca Prica, MD, Rodger Tiedemann, MD PhD, Suzanne Trudel, MD, Vishal Kukreti, MD
Journal: Blood
Blood (2016) 128 (22): 2137.
https://doi.org/10.1182/blood.V128.22.2137.2137
Published: 2016
Journal Articles

High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.

Jonathan Keats, PhD, Rodger Tiedemann, MD, PHD, Roelendt Schop, MD, Michael Sebag, MD, PHD, Marta Chesi, PHD, Scott Van Wier, Chang-Xin Shi, Yuan-Xiao Zhu, Angela Baker, PHD, Homer Fogle, Catherine Mancini, Tae-Hoon Chung, Philip Greipp, MD, Angela Dispenzieri, MD, Michael Barrett, PHD, Laurakay Bruhin, Keith Stewart, MD, John Carpten, PHD, Rafael Fonseca, MD, Peter Leif Bergsagel, MD
Journal: Blood
Blood (2006) 108 (11): 3407.
https://doi.org/10.1182/blood.V108.11.3407.3407
Published: 2006